Metaclipse Therapeutics
Develops membrane‑based biological adjuvant platforms for personalized cancer immunotherapies and virus‑like particle vaccines for infectious disease prevention. Focus areas include engineering membrane‑anchored immunostimulatory proteins linked to antigen sources, preclinical validation in animal models, cGMP process development, and progression to first‑in‑human Phase 1 studies and regulatory filings.
Industries
Nr. of Employees
small (1-50)
Metaclipse Therapeutics
Products
Personalized autologous membrane‑vesicle immunotherapy (investigational)
A personalized vaccine approach produced from a patient’s tumor membrane vesicles modified with membrane‑anchored immunostimulatory proteins to present patient‑specific tumor antigens.
Virus‑like particle vaccine platform with membrane‑anchored adjuvants (investigational)
VLP‑based vaccine constructs modified with membrane‑anchored adjuvants designed to induce robust humoral and cellular responses, evaluated for infectious disease prevention.
HER2-membrane vaccine product
A membrane vesicle-based immunotherapy product developed by Metaclipse Therapeutics, led by Dr. Kristen Jacobsen.
Membrex™ personalized immunotherapy
A personalized immunotherapy platform developed by Metaclipse Therapeutics, used in combination with immune checkpoint inhibitors for treatment of various cancers including nasopharyngeal carcinoma, head and neck cancer, colon cancer, triple negative breast cancer, and recurrent/metastatic head and neck squamous cell carcinoma.
VaxRex™
An investigational therapy using proprietary biological adjuvants for therapeutic and preventative vaccines, not yet approved by FDA or other regulatory agencies.
Personalized autologous membrane‑vesicle immunotherapy (investigational)
A personalized vaccine approach produced from a patient’s tumor membrane vesicles modified with membrane‑anchored immunostimulatory proteins to present patient‑specific tumor antigens.
Virus‑like particle vaccine platform with membrane‑anchored adjuvants (investigational)
VLP‑based vaccine constructs modified with membrane‑anchored adjuvants designed to induce robust humoral and cellular responses, evaluated for infectious disease prevention.
HER2-membrane vaccine product
A membrane vesicle-based immunotherapy product developed by Metaclipse Therapeutics, led by Dr. Kristen Jacobsen.
Membrex™ personalized immunotherapy
A personalized immunotherapy platform developed by Metaclipse Therapeutics, used in combination with immune checkpoint inhibitors for treatment of various cancers including nasopharyngeal carcinoma, head and neck cancer, colon cancer, triple negative breast cancer, and recurrent/metastatic head and neck squamous cell carcinoma.
VaxRex™
An investigational therapy using proprietary biological adjuvants for therapeutic and preventative vaccines, not yet approved by FDA or other regulatory agencies.
Services
Design and preclinical evaluation of membrane‑based vaccines and immunotherapies, including in vivo efficacy, immunogenicity and combination studies.
Scale‑up and process development for cGMP production of immunostimulatory proteins and vaccines to support clinical studies.
Development, qualification and validation of protein analytical methods, assay development for vaccine products, and clinical quality control support.
Design and preclinical evaluation of membrane‑based vaccines and immunotherapies, including in vivo efficacy, immunogenicity and combination studies.
Scale‑up and process development for cGMP production of immunostimulatory proteins and vaccines to support clinical studies.
Development, qualification and validation of protein analytical methods, assay development for vaccine products, and clinical quality control support.
Expertise Areas
- Personalized cancer vaccine development
- Vaccine adjuvant engineering
- Preclinical tumor and infectious disease models
- cGMP bioprocess development and scale‑up
Key Technologies
- Membrane vesicle engineering
- Membrane‑anchored cytokine/adjuvant display
- Virus‑like particle (VLP) vaccine platforms
- Protein transfer surface engineering
News & Updates
Award of a one‑year NCI SBIR contract to advance preclinical development of a membrane‑vesicle personalized immunotherapy combined with an mRNA vaccine prime‑boost approach for nasopharyngeal carcinoma.
Selected as one of the 2025 Rising Stars by BioNTX.
Award of a $6M Cancer Prevention Research Institute of Texas (CPRIT) grant to support Phase 1 development of the personalized membrane‑vesicle immunotherapy in combination with immune checkpoint inhibition for head and neck cancer.
Regulatory clearance of IND applications enabling first‑in‑human Phase 1 clinical trials of the personalized membrane‑vesicle immunotherapy in triple negative breast cancer and head and neck cancer.
Series of SBIR contracts and grants to support influenza and SARS‑CoV‑2 vaccine development for elderly populations and product development activities.
Award of a one‑year NCI SBIR contract to advance preclinical development of a membrane‑vesicle personalized immunotherapy combined with an mRNA vaccine prime‑boost approach for nasopharyngeal carcinoma.
Selected as one of the 2025 Rising Stars by BioNTX.
Award of a $6M Cancer Prevention Research Institute of Texas (CPRIT) grant to support Phase 1 development of the personalized membrane‑vesicle immunotherapy in combination with immune checkpoint inhibition for head and neck cancer.
Regulatory clearance of IND applications enabling first‑in‑human Phase 1 clinical trials of the personalized membrane‑vesicle immunotherapy in triple negative breast cancer and head and neck cancer.
Series of SBIR contracts and grants to support influenza and SARS‑CoV‑2 vaccine development for elderly populations and product development activities.